A rumour surfaced in the press last week suggesting that Pfizer was likely to buy Enzon.

Enzon is a leader in the field of PEGylation, which is a way of extending the time certain drugs stay in the body in order to improve results.

To us at Longbow this represents the clear endorsement that we are on the right tracks with our investment in Polytherics as we believe that they can do a better job.

It does not actually matter whether or not the rumour is true, the fact that the market “thinks” it likely means that PEGylation is coming of age.